Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 126

  • 3 926 clinical trials
  • 1 543 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Non-small cell lung cancer332Breast cancer170Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic106Prostate cancer102Colorectal cancer90Ovarian cancer90Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Chronic lymphocytic leukaemia80Malignant melanoma79Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV59Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+682

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 926 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 926 clinical trials

Colorectal cancer metastatic

Recruiting

Study Comparing Trifluridine/Tipiracil with Panitumumab or Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Breast cancer metastatic

Recruiting

Study on the Effectiveness of Durvalumab for Patients with Metastatic Breast Cancer in Early Chemotherapy Stages

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Unicancer

Glioblastoma

Recruiting

A study of 5-aminolevulinic acid with radiotherapy (radiodynamic therapy) for patients with first recurrence of glioblastoma brain tumor

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aminolevulinic Acid Hydrochloride
  • Sponsor:Universitaet Muenster

HER2 positive breast cancer

Recruiting

Study on Reducing Treatment for Patients with HER2-Positive Metastatic Breast Cancer Using Trastuzumab and Drug Combination After 2 Years of Controlled Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Unicancer

Neuroendocrine carcinoma

Recruiting

Study Comparing FOLFIRINOX and Cisplatin-Etoposide for Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Craniopharyngioma

Recruiting

A Study of Dabrafenib and Trametinib Treatment Before and After Surgery in Patients with Papillary Craniopharyngioma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Dabrafenib
  • Sponsor:Region Skane

Neoplasm

Recruiting

Study on Everolimus and Drug Combination for Children with Relapsed or Refractory Pediatric Cancer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Substances:Avelumab
  • Sponsor:Institut Gustave Roussy

Adenocarcinoma pancreas

Recruiting

Study on 68Ga-FAPI-46 for Imaging in Patients with Non-Metastatic Pancreatic Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Institut Curie

Study on Luspatercept and Epoetin Alfa for Patients with Low-Risk Myelodysplastic Syndrome Without Ring Sideroblasts Who Did Not Respond to ESA

Recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Epoetin Alfa
  • Sponsor:Groupe Francophone Des Myelodysplasies

Prostate cancer

Recruiting

Study on the Use of 18F-PSMA-1007 PET/MRI for Diagnosing Significant Prostate Cancer in Patients with Suspected Prostate Cancer

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Ospedale San Raffaele S.r.l.

Breast cancer+2

Recruiting

Study Comparing Trastuzumab Deruxtecan with a Drug Combination for Patients with HER2+ Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:WSG Women's Cancer Study Group GmbH

Hepatocellular carcinoma

Recruiting

Study on Durvalumab and Tremelimumab for Liver Cancer Patients Undergoing Electroporation Ablation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab467 clinical trialsCarboplatin344 clinical trialsCisplatin288 clinical trialsPaclitaxel266 clinical trialsFluorouracil239 clinical trialsOxaliplatin230 clinical trialsNivolumab218 clinical trialsDexamethasone169 clinical trialsDurvalumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.